Micromet teams with US NCI to expand BiTE antibody development
This article was originally published in Scrip
Executive Summary
With the aid of the US National Cancer Institute (NCI), Micromet is expanding the development of its BiTE antibody blinatumomab in patients with acute lymphoblastic leukaemia (ALL) and various sub-types of lymphoma.